J Clin Chem Clin Biochem 1978,16(9):533–534.PubMed 46. Gerova M, Halgasova N, Ugorcakova J, Bukovska G: Endolysin of bacteriophage

BFK20: PX-478 price evidence of a catalytic and a cell wall binding domain. FEMS Microbiol Lett 2011,321(2):83–91.PubMedCrossRef Competing interests The authors have no competing interests to declare. Authors’ contributions YHY and QP conducted the protein analysis. YHY performed the bioinformatics buy GSK3326595 analyses. MYG supervised the work. MYG and YHY designed the study and wrote the manuscript. All authors reviewed and approved the final version of the manuscript.”
“Background DNA vaccination has gained a lot of attention since its ability to induce long-lasting humoral and cellular immune responses against an encoded antigen was discovered [1]. In addition, DNA vaccination poses no danger of integration into host cellular DNA thereby raising its safety profile [2–4]. DNA vaccines can be easily isolated to high purity, encode multiple

antigens, and possess inherent adjuvant activity due to the presence of unmethylated CpG motifs that are recognized in mammals by TLR9 [5]. So called purified “Naked” DNA vaccination was shown to be highly efficient in rodents and mice, but not in larger animals and humans [6]. Consequently, it is very important to optimize DNA vaccine vectors and develop a delivery system to facilitate cellular uptake and enhance gene transfer efficiency and expression in situ[7]. Several strategies have been explored to protect plasmids from this website degradation, facilitating DNA uptake by phagocytic Antigen Presenting Cells (APCs) and thereby enhancing their immunological properties. This includes delivery technologies based on encapsulation into synthetic particles (cationic liposomes or polymers) or the use of viral vectors [7, 8]. Despite their potential, some limitations and safety issues still remain which can restrict the application of gene therapy – e.g. the complexity of producing liposomes and their limited packaging capacity

[9]. Additionally, it was shown that some viral vectors have the capacity to randomly integrate their genetic material into the host genome causing insertional mutagenesis of a cellular oncogene, leading 5-Fluoracil to tumour formation [10]. The use of bacteria as delivery vehicles for DNA vaccination has emerged as an interesting alternative to overcome many of the problems associated with viral or liposomal delivery [11]. W. Schaffner was the first to observe genetic material transfer from bacteria to mammalian cells [12]. Since then, bacteria have been extensively exploited as vaccine delivery vehicles for vaccination against bacterial and viral pathogens as well as cancer immunotherapy [13–15]. The use of bacteria for mucosal delivery of DNA vaccines may be advantageous due to their potential to elicit secretory IgA responses as well as systemic immunity, when compared to conventional parenteral immunization [16].